RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q2 2026
Top Holdings84 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
| 10.3M | $2.7B | 23.8% | $266.72 | -7.05% | 1 qtr | New 98 | |
| 28.9M | $791.9M | 6.9% | $27.37 | +42.89% | 1 qtr | New 98 | |
RHYTHM PHARMACEUTICALS INC | 6.7M | $740.2M | 6.4% | $38.85 | +175.84% | 31 qtrssince 2018-Q4 | Unchanged 0 |
VAXCYTE INC | 11.5M | $667M | 5.8% | $49.77 | +20.22% | 25 qtrssince 2020-Q2 | Unchanged 0 |
SIONNA THERAPEUTICS INC | 9.9M | $435.7M | 3.8% | $11.56 | -49.22% | 6 qtrssince 2025-Q1 | Unchanged 0 |
TYRA BIOSCIENCES INC | 12.2M | $389.6M | 3.4% | $15.72 | +58.62% | 20 qtrssince 2021-Q3 | Unchanged 0 |
EDGEWISE THERAPEUTICS INC | 8.4M | $341M | 3.0% | $17.63 | +142.52% | 10 qtrssince 2024-Q1 | Decreased 0 |
NEWAMSTERDAM PHARMA COMPANY | 9.6M | $323.7M | 2.8% | $14.11 | +83.59% | 15 qtrssince 2022-Q4 | Unchanged 0 |
| 7.8M | $286.8M | 2.5% | $36.73 | +22.08% | 1 qtr | New 80 | |
SEPTERNA INC | 7M | $234.3M | 2.0% | $23.23 | +67.50% | 7 qtrssince 2024-Q4 | Unchanged 0 |
BICARA THERAPEUTICS INC | 7.3M | $215.4M | 1.9% | $25.13 | -6.76% | 8 qtrssince 2024-Q3 | Unchanged 0 |
MINERALYS THERAPEUTICS INC | 7.7M | $207.6M | 1.8% | $19.13 | +33.83% | 14 qtrssince 2023-Q1 | Unchanged 0 |
GH RESEARCH PLC | 7.6M | $205.3M | 1.8% | $16.40 | +70.40% | 21 qtrssince 2021-Q2 | Decreased 0 |
DISC MEDICINE INC | 2.5M | $179.2M | 1.6% | $58.68 | +36.39% | 6 qtrssince 2025-Q1 | Unchanged 0 |
| 8M | $178.6M | 1.6% | $26.75 | -1.23% | 2 qtrssince 2026-Q1 | Unchanged 0 | |
ARTIVA BIOTHERAPEUTICS INC | 18M | $174.2M | 1.5% | $12.07 | -8.08% | 8 qtrssince 2024-Q3 | Increased 74 |
JANUX THERAPEUTICS INC | 11.2M | $171.9M | 1.5% | $27.88 | -35.32% | 21 qtrssince 2021-Q2 | Unchanged 0 |
TAYSHA GENE THERAPIES INC | 23.6M | $160.4M | 1.4% | $2.74 | +110.58% | 12 qtrssince 2023-Q3 | Unchanged 0 |
BIOCRYST PHARMACEUTICALS INC | 15.8M | $158.3M | 1.4% | $7.80 | +25.90% | 3 qtrssince 2025-Q4 | Unchanged 0 |
WAVE LIFE SCIENCES LTD | 27M | $156.7M | 1.4% | $17.73 | -71.57% | 31 qtrssince 2018-Q4 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $11.5B across 84 positions as of Q2 2026. Top holdings: ASND (23.8%), PBLS (6.9%), RYTM (6.4%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
Active quarter - 17 new positions, 18 exits, 10 increased. Top move: ASND (NEW, conviction 98). Portfolio: $11.5B across 84 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR